Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 633.00
Bid: 628.00
Ask: 629.50
Change: -12.00 (-1.86%)
Spread: 1.50 (0.239%)
Open: 641.50
High: 643.00
Low: 628.00
Prev. Close: 645.00
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Debt

5 Aug 2019 15:00

RNS Number : 9418H
Tate & Lyle PLC
05 August 2019
 

5 August 2019

 

TATE & LYLE PLC - ISSUE OF DEBT

 

ISSUE OF DEBT - NOT FOR DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA (OR TO U.S. PERSONS), AUSTRALIA, CANADA OR JAPAN, OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES OF SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW.

Tate & Lyle PLC announces that on 1 August 2019 it priced a US$200 million debt private placement. The proceeds will be used to refinance existing indebtedness, thereby extending the Group's debt maturity profile, and for general corporate purposes.

The transaction is expected to complete on 19 November 2019, when the following notes will be issued:

$100 million 3.31% notes due 2029

$100 million 3.41% notes due 2031

Commenting on the issue, Imran Nawaz, Chief Financial Officer, said: "We are delighted by the strong support shown again by private placement investors in Tate & Lyle. The notes will enable us to refinance the £200 million 6.75% bond that matures in November 2019, while maintaining strong levels of liquidity and extending the average maturity of our debt. Issuing fixed-rate notes has allowed us to lock into attractive long-term interest rates, and achieve a cost reduction compared to the maturing debt".

Disclaimer

The notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Act") and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Act. This notice is for information only, does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

END

 

For more information contact Tate & Lyle PLC:

Investor Relations

Tel: +44 (0) 20 7257 2111

 

About Tate & Lyle: 

Tate & Lyle is a global provider of solutions and ingredients for food, beverage and industrial markets.

Tate & Lyle operates through two global divisions, Food & Beverage Solutions and Primary Products, supported by the Innovation and Commercial Development and Global Operations teams. Food & Beverage Solutions is focused on growth by building leading positions globally in the categories of beverages, dairy, and soups, sauces and dressings. Primary Products is focused on delivering steady earnings and generating cash.

Food & Beverage Solutions consists of: Texturants, including speciality starches; Sweeteners, including low- and no-calorie sweeteners; and a Health and Wellness portfolio comprising mainly speciality fibres; and Stabilisers and Functional Systems, which are bespoke ingredient blends that ensure foods retain their structure.

Primary Products consists of high-volume sweeteners, industrial starches and fermentation products (primarily acidulants). It also sells co-products from the corn milling process as animal nutrition.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2019, Tate & Lyle sales totalled £2.8 billion. For more information, please visit http://www.tateandlyle.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IODUGUQWRUPBGWA
Date   Source Headline
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company
21st Mar 20244:10 pmRNSHolding(s) in Company
20th Mar 20243:00 pmRNSHolding(s) in Company
20th Mar 202412:00 pmRNSHolding(s) in Company
19th Mar 20242:00 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
12th Mar 20244:24 pmRNSHolding(s) in Company
12th Mar 20244:22 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNSDirectorate Change
4th Mar 20242:00 pmRNSDirector/PDMR Shareholding
4th Mar 20241:45 pmRNSHolding(s) in Company
28th Feb 20242:30 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSTrading Statement
1st Feb 202412:00 pmRNSTotal Voting Rights
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report
8th Nov 20237:00 amRNSDirectorate Change
23rd Oct 202310:30 amRNSHolding(s) in Company
16th Oct 202310:30 amRNSHolding(s) in Company
13th Oct 202310:30 amRNSHolding(s) in Company
12th Oct 202311:00 amRNSHolding(s) in Company
2nd Oct 202310:23 amRNSDirector Declaration
1st Sep 202311:00 amRNSTotal Voting Rights
25th Aug 20233:45 pmRNSHolding(s) in Company
17th Aug 20234:30 pmRNSHolding(s) in Company
15th Aug 20234:30 pmRNSHolding(s) in Company
10th Aug 20234:00 pmRNSHolding(s) in Company
7th Aug 202312:15 pmRNSDirector/PDMR Shareholding
3rd Aug 20233:45 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.